HRV Pharma has entered into definitive agreements to acquire 100 per cent of the equity of Phatebo GmbH from ZeroStack Corp.
Phatebo is a licensed pharmaceutical company based in Hilzingen, Germany, specialising in clinical trial supply, with revenues of approximately ₹350 crore in 2025. The terms of the transaction were not disclosed. The acquisition takes HRV beyond active pharmaceutical ingredients into finished formulations, and gives HRV a licensed operating business in Germany.
Founded in 2015, Phatebo holds a German pharmaceutical wholesale authorisation and has built its business around this work. It sources investigational, comparator and ancillary medicines, including innovative branded therapies, for global pharmaceutical companies and clinical research organisations.
It operates quality systems built for good distribution practice, and it also trades in pharmaceuticals and medical devices across Europe and international markets, according to a release.
Published on November 3, 2026
